226 related articles for article (PubMed ID: 27547001)
1. Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance.
Jiménez-Pérez M; González-Grande R; España Contreras P; Pinazo Martínez I; de la Cruz Lombardo J; Olmedo Martín R
World J Gastroenterol; 2016 Aug; 22(29):6573-81. PubMed ID: 27547001
[TBL] [Abstract][Full Text] [Related]
2. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Takeda H; Ueda Y; Inuzuka T; Yamashita Y; Osaki Y; Nasu A; Umeda M; Takemura R; Seno H; Sekine A; Marusawa H
Sci Rep; 2017 Mar; 7():45605. PubMed ID: 28361915
[TBL] [Abstract][Full Text] [Related]
3. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
4. Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Zhang Y; Cao Y; Zhang R; Zhang X; Lu H; Wu C; Huo N; Xu X
PLoS One; 2016; 11(11):e0165658. PubMed ID: 27812165
[TBL] [Abstract][Full Text] [Related]
5. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
6. Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients.
Sede MM; Laufer NL; Quarleri J
Int J Antimicrob Agents; 2015 Aug; 46(2):219-24. PubMed ID: 26100213
[TBL] [Abstract][Full Text] [Related]
7. Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Soñora M; Cristina J; Moratorio G; Hernández N; Moreno P
BMC Infect Dis; 2021 Apr; 21(1):387. PubMed ID: 33902462
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.
Costilla V; Mathur N; Gutierrez JA
Clin Liver Dis; 2015 Nov; 19(4):641-56, vi. PubMed ID: 26466653
[TBL] [Abstract][Full Text] [Related]
9. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
10. Primer ID ultra-deep sequencing reveals dynamics of drug resistance-associated variants in breakthrough hepatitis C viruses: relevance to treatment outcome and resistance screening.
Barnard R; Chopra A; James I; Blinco J; Watson MW; Jabara CB; Hazuda D; Lemon SM; Mallal S; Gaudieri S
Antivir Ther; 2016; 21(7):567-577. PubMed ID: 27219495
[TBL] [Abstract][Full Text] [Related]
11. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
[TBL] [Abstract][Full Text] [Related]
13. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants.
Premoli C; Aghemo A
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):76-87. PubMed ID: 26448306
[TBL] [Abstract][Full Text] [Related]
14. Treatment failure with DAA therapy: Importance of resistance.
Sarrazin C
J Hepatol; 2021 Jun; 74(6):1472-1482. PubMed ID: 33716089
[TBL] [Abstract][Full Text] [Related]
15. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure.
Mohamed S; Bourliere M; Benali S; Oules V; Castellani P; Khiri H; Camus C; Penaranda G; Chiche L; Gonzalez D; Sayada C; Olive D; Halfon P
J Clin Virol; 2016 May; 78():36-43. PubMed ID: 26971166
[TBL] [Abstract][Full Text] [Related]
17. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
19. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
Chayama K; Hayes CN
Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
[TBL] [Abstract][Full Text] [Related]
20. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Ogert RA; Howe JA; Vierling JM; Kwo PY; Lawitz EJ; McCone J; Schiff ER; Pound D; Davis MN; Gordon SC; Ravendhran N; Rossaro L; Jacobson IM; Ralston R; Chaudhri E; Qiu P; Pedicone LD; Brass CA; Albrecht JK; Barnard RJ; Hazuda DJ; Howe AY
Antivir Ther; 2013; 18(3):387-97. PubMed ID: 23406826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
